Showing 4831-4840 of 21484 results for "".
- New Tralokinumab Data Focus On High-Burden Atopic Dermatitishttps://reachmd.com/news/new-tralokinumab-data-focus-on-high-burden-atopic-dermatitis/2488608/LEO Pharma presented new analyses of tralokinumab (Adtralza; Adbry [tralokinumab-ldrm]) in adults and adolescents with atopic dermatitis (AD) at the 35th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, including real-world findings from TRACE, pha
- Evolving Dietary Strategies for Menopause: Balancing Vegan and High-Fat Approacheshttps://reachmd.com/news/evolving-dietary-strategies-for-menopause-balancing-vegan-and-high-fat-approaches/2474906/Clinicians are increasingly challenged to integrate dietary strategies into menopause care as patient demand grows for nonpharmacologic relief of hot flashes and weight gain. Rece
- Phase 2 DLE Trial Meets Primary Endpoint With Daxdilimabhttps://reachmd.com/news/eadv-phase-2-dle-trial-meets-primary-endpoint-with-daxdilimab/2488598/Daxdilimab improved measures of disease activity in adults with moderate-to-severe discoid lupus erythematosus (DLE), according to new data from a phase 2 trial presented at EADV 2026. Researchers included 72 adults aged 18 to 75 years with chronic, treatment-refrac
- Kenvue Presents New Skin and Hair Research at EADV 2026https://reachmd.com/news/kenvue-presents-new-skin-and-hair-research-at-eadv-2026/2488594/New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 examines topical formulations containing niacinamide, trehalose, colloidal oat, and minoxidil across several skin and hair concerns. Kenvue announced 12 data sets invol
- Three-Year Data Detail Bimekizumab Outcomes in Hidradenitis Suppurativahttps://reachmd.com/news/three-year-data-detail-bimekizumab-outcomes-in-hidradenitis-suppurativa/2488593/New analyses of the Phase 3 BE HEARD clinical program presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 evaluated long-term inflammatory lesions, tunnels, quality of life, and safety with bimekizumab (Bimzelx; UCB) in adults with moderate
- Tulisokibart Meets Phase 2b Primary Endpoint in Hidradenitis Suppurativahttps://reachmd.com/news/tulisokibart-meets-phase-2b-primary-endpoint-in-hidradenitis-suppurativa/2488592/Tulisokibart, an investigational monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), met the primary endpoint in a Phase 2b trial evaluating the therapy in patients with moderate-to-severe hidradenitis suppurativa (HS), according to results presente
- New LATITUDE Data Detail Zasocitinib Efficacy, Durability in Plaque Psoriasishttps://reachmd.com/news/new-latitude-data-detail-zasocitinib-efficacy-durability-in-plaque-psoriasis/2488590/New Phase 3 data presented at the European Academy of Dermatology & Venereology (EADV) Congress 2026 showed higher skin clearance rates with investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) compared with deucravacitinib in adults with modera
- Olumiant Gains FDA Approval for Severe Alopecia Areata in Patients 12 and Olderhttps://reachmd.com/news/olumiant-gains-fda-approval-for-severe-alopecia-areata-in-patients-12-and-older/2488595/The FDA has approved Eli Lilly and Company’s Olumiant (baricitinib) for patients aged 12 years and older with severe alopecia areata (AA), expanding the oral Janus kinase (JAK) inhibitor’s US indication to adolescents, according to an announcement from the manufacturer. The
- Drain Omission, Somatostatin Analogues Cut Pancreatic Fistulahttps://reachmd.com/news/drain-omission-somatostatin-analogues-cut-pancreatic-fistula/2488576/Key Takeaways Among patients after partial pancreatectomy, pooled clinically relevant grade B/C fistula incidence was 15.1% overall, 14.2% after pancreatoduodenectomy, and 19.1% after left pancreatectomy. Omitting drains after left pancreatectomy was associated with
- Review Finds Progress in Mitochondrial Disease Trials Where Drug, Genotype, and Endpoint Alignhttps://reachmd.com/news/review-finds-progress-in-mitochondrial-disease-trials-where-drug-genotype-and-endpoint-align/2488585/Key Takeaways A review in Biomedicine & Pharmacotherapy surveyed 159 ClinicalTrials.gov studies of primary mitochondrial diseases (PMDs), including 110 interventional trials, and concludes that drug development may be at a turning poi